125 results on '"Lundberg, Ingrid E."'
Search Results
2. Current myositis clinical trials and tribulations.
3. Low copy numbers of complementC4andC4Adeficiency are risk factors for myositis, its subgroups and autoantibodies
4. The EuroMyositis registry: an international collaborative tool to facilitate myositis research
5. Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study
6. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial
7. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
8. Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case–control study
9. 08.10 Serum lipid and fatty acid profiles are altered in patients with polymyositis or dermatomyositis
10. 02.09 Identification of a novel pro-inflammatory T cell epitope from his-trna-synthetase associated with interstitial lung disease in anti-jo-1 positive patients
11. Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases
12. Nitrosative modifications of the Ca2+ release complex and actin underlie arthritis-induced muscle weakness
13. Differences and similarities in rheumatology specialty training programmes across European countries
14. Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease
15. Familial aggregation and heritability: a nationwide family-based study of idiopathic inflammatory myopathies
16. Patients with regular physical activity before onset of rheumatoid arthritis present with milder disease
17. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up
18. Response to: ‘Correspondence on ‘EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups’’ by Irfanet al
19. TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis
20. Familial aggregation and heritability: a nationwide family-based study of idiopathic inflammatory myopathies.
21. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies
22. Response to: ‘Comment on: standardisation of myositis-specific antibodies: where are we today?’ by Infantino et al
23. Response to: ‘Semi-quantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?’ by Cavazzana et al
24. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups
25. Response to: ‘Comment on: ‘Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria’ by Greco et al’ by Knitza et al
26. Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies
27. Response to: ‘Time to personalise the treatment of anti-MDA-5 associated lung disease’ by Lake et al
28. Response to: ‘Detection of myositis-specific antibodies: additional notes’ by Infantino et al
29. Response to: ‘Detection of myositis-specific antibodies’ by Vulstekeet al
30. Response to: ‘Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice’ by Hočevar et al
31. Response to: ‘Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria’ by Cavagnaet al
32. Response to: '2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?' by Malaviya
33. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial
34. The EuroMyositis registry: an international collaborative tool to facilitate myositis research
35. Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study
36. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis
37. Response to: 'Correspondence on 'EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups" by Irfan et al.
38. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups
39. Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases
40. Nitrosative modifications of the Ca2+release complex and actin underlie arthritis-induced muscle weakness
41. A8.24 autophagy may contribute to glucocorticoid resistance in myositis patients by maitaining muscle T cells homeostasis
42. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up
43. A3.11 Immunosuppressive Effects of Glucocorticoids and Regulatory T Cells on CD28null T Cells in Vitro
44. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups.
45. TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis
46. Low serum levels of vitamin D in idiopathic inflammatory myopathies
47. Activated LTB4 pathway in muscle tissue of patients with polymyositis or dermatomyositis
48. Effect of immunosuppressive treatment on gene expression in muscle from patients with polymyositis and dermatomyositis
49. HMGB1 mediates muscle fatigue via TLR4 - a possible mechanism for muscle fatigue in patients with inflammatory myopathies
50. Persisting CD28nullT cells, but not regulatory T cells, in muscle tissue of myositis patients after immunosuppressive therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.